This Article Abstract Full Text (PDF) All Versions of this Article: jhc.2008.951772v1 56/11/995    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, L. U. Articles by Vainzof, M. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, L. U. Articles by Vainzof, M. Social Bookmarking                         What's this?

Muscle Protein Alterations in LGMD2I Patients With Different Mutations in the Fukutin-related Protein Gene

Lydia U. Yamamoto, Fernando J. Velloso, Bruno L. Lima, Luciana L.Q. Fogaça, Flávia de Paula, Natássia M. Vieira, Mayana Zatz and Mariz Vainzof

Human Genome Research Center, Biosciences Institute, University of São Paulo, São Paulo, Brazil

Correspondence to: Mariz Vainzof, PhD, Human Genome Research Center, IB-USP, R. Matão, 106–Cidade Universitária, São Paulo, SP–CEP 05508-900, Brazil. E-mail: mvainzof{at}usp.br

	Summary

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

 
Fukutin-related protein (FKRP) is a protein involved in the glycosylation of cell surface molecules. Pathogenic mutations in the FKRP gene cause both the more severe congenital muscular dystrophy Type 1C and the milder Limb-Girdle Type 2I form (LGMD2I). Here we report muscle histological alterations and the analysis of 11 muscle proteins: dystrophin, four sarcoglycans, calpain 3, dysferlin, telethonin, collagen VI, -DG, and 2-laminin, in muscle biopsies from 13 unrelated LGMD2I patients with 10 different FKRP mutations. In all, a typical dystrophic pattern was observed. In eight patients, a high frequency of rimmed vacuoles was also found. A variable degree of 2-laminin deficiency was detected in 12 patients through immunofluorescence analysis, and 10 patients presented -DG deficiency on sarcolemmal membranes. Additionally, through Western blot analysis, deficiency of calpain 3 and dystrophin bands was found in four and two patients, respectively. All the remaining proteins showed a similar pattern to normal controls. These results suggest that, in our population of LGMD2I patients, different mutations in the FKRP gene are associated with several secondary muscle protein reductions, and the deficiencies of 2-laminin and -DG on sections are prevalent, independently of mutation type or clinical severity. (J Histochem Cytochem 56:995–1001, 2008)

Key Words: LGMD2I • fukutin-related protein • muscular dystrophies • muscle proteins

	Introduction

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

 
THE FUKUTIN-RELATED PROTEIN (FKRP) gene was identified through its homology to the fukutin gene, which causes Fukuyama muscular dystrophy (FMD). FKRP has been predicted to be a type II transmembrane protein and, because of the sequence similarities to many glycosyltransferases, such as fukutin, it is predicted to be a phospholigand transferase (Brockington et al. 2001a; Grewal and Hewitt 2003; Hewitt and Grewal 2003).

Pathogenic mutations in the FKRP gene result in muscular dystrophy (MD) phenotypes, which were identified in congenital MD Type 1C (MDC-1C) and Limb-Girdle MD Type 2I (LGMD2I) (Brockington et al. 2001a,b). Both MDC and LGMD2I are heterogeneous groups of autosomal recessively inherited muscle diseases. MDC is characterized by onset of symptoms within the first few months of life, and in the 1C form, patients never acquire ambulation. LGMD2I has a milder and variable course, with the age at onset varying from the first to the fourth–fifth decade of life and slower progression. In both conditions, serum creatine kinase is elevated and intelligence is preserved, although structural brain changes have been detected in some patients with FKRP mutations (Topaloglu et al. 2003; Mercuri et al. 2006; Quijano-Roy et al. 2006).

Components of the extracellular matrix, such as 2-laminin, integrin -7, and collagen VI, interact with most defective proteins responsible for MDC, whereas the defects responsible for the LGMD forms are largely associated with sarcolemmal proteins , β, , and -sarcoglycans, caveolin, dysferlin, and sarcomeric proteins such as telethonin and myotilin (Brockington et al. 2002; Bushby and Beckmann 2003). Although MDC-1C and LGMD2I are allelic disorders, it became clear that, in addition to the clinical and pathological heterogeneity, they are also genetically diverse. Different types of mutation cause MDC-1C, whereas the majority of the LGMD2I patients already described carry a common C826A missense mutation in the FKRP gene (Mercuri et al. 2003; Wicklund and Hilton-Jones 2003; Brown et al. 2004).

Although the function of FKRP is still unknown, it has been suggested that it might be involved in the glycosylation of -DG in muscle membrane. The DG complex is important in muscle formation and maintenance and cell adhesion, and it also plays an important role in the function of other tissues, such as brain, kidneys, and peripheral nerves. A single gene DAGI encodes a polypeptide that is post-translationally modified to yield the two glycoproteins referred to as - and β-DG (Michele et al. 2002; Martin 2003; Cohn 2005). -DG is a heavily glycosylated peripheral membrane component of the dystrophin-associated–glycoprotein complex (DGC), whereas β-DG is a transmembrane protein that links to dystrophin intracellularly. The disruption of this linkage underlies several forms of MD, underscoring its importance in striated muscle, which contributes to the structural integrity of the sarcolemma (Ervasti and Campbell 1993).

Providing evidence for the glycosyltransferase function of FKRP, patients with MDC-1C typically show abnormalities of -DG glycosylation, in addition to a secondary reduction in 2-laminin (Brockington et al. 2001b). All studied patients with this severe form had a variable secondary reduction in 2-laminin expression, which was less marked than the reduction in -DG (Brockington et al. 2002; Brown et al. 2004). Moreover, muscle biopsy findings seem to be less uniform in patients with LGMD2I. Analysis of muscle biopsies has shown variable secondary protein abnormalities, and unlike MDC-1C, detection of abnormal 2-laminin chain on IHC is not so remarkable (Poppe et al. 2003).

Because FKRP protein cannot be easily measured, secondary effects on muscle protein presence and organization can be used as additional information on the mechanism of the disease and could explain the huge clinical variability observed among LGMD2I patients (de Paula et al. 2003). Here we report muscle biopsy analyses and the expression of muscle proteins of the sarcolemma (dystrophin, four sarcoglycans, dysferlin), extracellular matrix (2-laminin, -DG, collagen VI), sarcomere (telethonin), and cytosol (calpain 3) in 13 LGMD2I families with 10 different mutations in the FKRP gene.

	Materials and Methods

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

 
Patients
We analyzed 13 unrelated LGMD2I patients with different mutations in the FKRP gene (Table 1 ). These patients were molecularly selected and clinically classified in a previous study of 86 Brazilian families (de Paula et al. 2003), ascertained in the Human Genome Research Center, Department of Biology, IB-USP, and classified as LGMD according to the criteria reported in Bushby (1995) and Bushby and Beckmann (2003). The study was performed after receiving the Institutional Human Subjects Review Board (IRB) approval. All patients signed the informed consent form before any procedure of the study.

Patients were classified according to the mutation into three groups: Group 1, four patients carrying the common C828A mutation in the homozygous state; Group 2, five patients homozygous for other mutations; and Group 3, four patients who were compound heterozygous for two different mutations in the FKRP gene (Table 1).

Muscle samples were obtained from biceps biopsies (for diagnostic purposes or after informed consent), frozen in liquid nitrogen immediately after removal, and stored at –70C until use. Routine histological and histochemical procedures were done, with staining for hematoxylin/eosin, modified Gomori trichrome, NADH, ATPase 9.4, 4.3, and acid and alkaline phosphatase (Dubowitz 1999).

Protein Studies
Protein analyses have been done in these patients since 1990 for diagnostic purposes. When sample material was available for analysis, new reactions were performed for this study.

Immunofluorescence Analysis
IHC analyses were performed, using simple or double reactions, as previously described (Vainzof et al. 2003, 2005). Briefly, four to six cryostat sections were thawed on polylysine-coated slides, air dried for 1 hr, and preincubated with PBS containing 10% horse serum (PBSS). The sections were incubated with primary antibodies for 6 hr at room temperature, washed three times with PBS, and incubated with anti-mouse or rabbit IgG-, FITC-, or CY3-conjugated secondary antibodies for 1 hr. After three additional washings, the sections were mounted with Vectashield (Vector Laboratories; London, UK) and analyzed under a Zeiss Axiophot microscope with epifluorescence (Carl Zeiss; Oberkochen, Germany). Image exposure time was standardized using the positive normal control for each reaction/antibody (Figure 1 ). The same exposure time was used for the images from each analyzed patient. Digital pictures were taken using the Axiovision 4.5 software (Carl Zeiss).

View larger version (88K): [in this window] [in a new window]   Figure 1 Histological and protein finding in one patient from each group of mutations: normal control (A–E); Patient 2, homozygote for the mutation C826A (F–J); Patient 6, homozygote for the mutation A545G (K–O); and Patient 13, compound heterozygote for the mutations C878T/C1073T (P–T). Hematoxylin/eosin histopathological finding (A,F,K,P), with rimmed vacuole in F (arrow). IHC findings: dystrophin immunostaining (B,G,L,Q), arrow in Q showing a labeled vacuole; 2-laminin, 80-kDa C-terminal antibody (C,H,M,R); and N-terminal 300-kDa antibody (D,I,N,S) and -DG (E,J,O,T). Bar = 50 µm.

View larger version (26K): [in this window] [in a new window]   Figure 2 Multiplex Western blot analysis for dystrophin, dysferlin, and calpain 3 in nine of the patients with Limb-Girdle Type 2I form of congenital muscular dystrophy. MYOSIN, myosin band detected in the Ponceau prestained blot for the evaluation of loaded muscle proteins.

	Results

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

Protein IHC Analysis
Immunofluorescence analysis of the skeletal muscle section showed no abnormalities for the expression of the proteins dystrophin, dysferlin, telethonin, , β, , and -sarcoglycans, or collagen VI in all patients.

A variable degree of deficiency in membrane labeling was observed for 2-laminin, mainly with the most sensitive N-terminal 300-kDa antibody, which showed a patchy and weaker pattern in 12 of the 13 studied patients. Labeling for -DG showed a total deficiency in 5 of 11 patients, a partial deficiency in 5 of 11 patients, and a normal pattern in 1 of the patients (Figure 1; Table 3 ).

	Discussion

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

 
Several recent studies have highlighted the role of the extensive O-linked glycan on -DG, mediating the binding of extracellular matrix proteins in skeletal muscle (Henry and Campbell 1999; Hewitt and Grewal 2003; Martin 2003). Studies from the Campbell group showed that -DG is a heavily glycosylated protein that migrates in a heterogeneous pattern on gels (Ibraghimov-Beskrovnaya et al. 1992). The protein is a dumbbell-shaped molecule, with two globular domains separated by a central rod thought to be the mucin-like domain, containing >50 potential sites for O-linked glycosylation on serine or threonine. The dystroglycan gene encodes an 70-kDa -chain polypeptide that migrates at 156 kDa in skeletal muscle because of extensive glycosylations. (Martin 2003). O-linked glycans from the mucin region have been sequenced from different sources, and an O-linked -mannose structure was found, which was elaborated with a sialyl-N-acetylglucosamine to yield NeuAc2, 3Galβ1, 4GlcNAcβ1, and 2Man-O-Ser/Th. In the skeletal muscle, the link of -DG to the basal lamina is done by the G domain of the 2 chain of laminin 2, which interacts with the glycans structures present on -DG. B-DG interacts with the C-terminal region of -DG at the membrane periphery and with dystrophin, utrophin, caveolin, actin, and Grb2 in the cytoplasm, thereby linking the extracellular matrix with cytoplasmic and signaling components of the muscle fibers (Henry and Campbell 1999).

Several glycosyltransferases are involved in this process of O-mannosyl oligosaccharide synthesis, such as POMT1 and POMGnT1, and mutations in the respective genes cause severe muscle diseases such as muscle-eye-brain disease and Walker-Warburg syndrome (Schachter et al. 2004). Other enzymes are putative glycosyltransferases. Among them, fukutin is involved in FMD, and mutations in the Large gene cause myodystrophy in mice and congenital MD Type 1D in humans (Hewitt and Grewal 2003; Schachter et al. 2004).

FKRP is also a putative glycosyltransferase, and its activity could play a significant role in the mechanism of glycosylation of -DG. In this case, different mutations in the FKRP gene could be associated with a diverse pattern of glycosylation of -DG. Beedle et al. (2007) recently showed that, in the muscle, the FKRP protein is associated with the sarcolemmal dystrophin glycoprotein complex (DGC) forming a stable mature complex. This study also reported that, in mouse models of MD in which DG is destabilized or lost, the FKRP is disrupted. Therefore, different mutations in the FKRP gene could result in the codification of enzymes with variable deficient glycosyltransferase activity. Consequently, the mucin domain of -DG would be diverse, resulting in variation in the link of the laminin molecule. This modulation in the organization of the dystrophin–glycoprotein complex could result in diverse patterns of disruption of this protein complex in the muscle of LGMD2I patients and could be correlated with their clinical course.

This was particularly observed in patients with the severe congenital MDC-1C form, in which the type of mutation in the FKRP gene was highly correlated with the disruption of membrane proteins associated with -DG (Matsumoto et al. 2005; MacLeod et al. 2007). All affected patients showed significant reduction of -DG and other membrane-associated proteins. In contrast, all LGMD2I patients that carry the most common C826A mutation have shown a less abnormal expression of proteins involved with -DG. The main findings were the association of a reduction of -DG with a marked reduction of 2-laminin on Western blot analysis, but this was not as clearly detectable by IHC (Brockington et al. 2001b; Poppe et al. 2003; Brown et al. 2004).

In our sample of 13 patients with a molecular diagnosis of LGMD2I, almost all showed a deficiency of 2-laminin in sections, mainly with the more sensitive N-terminal 300-kDa antibody. The LAMA2 gene codes a protein of 390 kDa, and under reducing conditions, the laminin 2 chain migrates as an N-terminal fragment of 300 kDa and a C-terminal fragment of 80 kDa. IHC studies have shown that partial deficiencies of the laminin 2 chain are more easily detected with the 300-kDa antibody than with the antibody against the 80-kDa fragment (Sewry et al. 1997). The use of more than one antibody is therefore more informative for this analysis.

Four patients were compound heterozygous for three different mutations, five were homozygous for four different mutations, and the remaining four were homozygous for the most common C826A mutation. Because we found a deficiency of laminin 2 in all these patients, this deficiency may not depend on the type of the mutation in the FKRP gene.

In contrast, comparing our four homozygous patients with the most common mutation, although all showed deficiency of 2-laminin on section, variability was observed for -DG expression. Because the used antibody for -DG detects the glycosylated part of the protein, the lack of detection of -DG on sarcolemma is a signal of defective glycosylation of the protein and not its total absence (Michele et al. 2002). In our sample, two patients were completely deficient, one was partially deficient, and one showed a positive IHC pattern for -DG in the muscle (comparable to normal control). This suggests no correlation between secondary reductions in these two extracellular matrix proteins, even under the effect of the same mutation.

Because none of the studied patients showed altered immunofluorescence pattern for dystrophin, dysferlin, telethonin, -, β-, -, -sarcoglycans, and collagen VI, glycosylation defects apparently do not perturb the organization of these proteins in the respective compartment in muscle fibers. However, a quantitative deficiency of dystrophin was observed in two patients, without correlation with the mutation or clinical course (Patients 10 and 12). As already observed in some Becker MD patients, a small quantitative reduction in the amount of dystrophin is not easily detectable by immunofluorescence analysis and can be more evident using Western blot methodology (Vainzof et al. 1992). Calpain 3 deficiency could be correlated with muscle degradation, because some samples of muscle biopsies have been maintained frozen for >15 years. In accordance with this fact, the four muscles that showed calpain 3 deficiencies were the oldest studied samples, and one of them showed several degraded bands in Western blot analysis (Patient 12). However, two patients carrying the same A545G mutation, biopsied in the same stage, were concordant for the partial deficiency of 2-laminin and -DG but discordant for calpain 3 amount. Calpain 3 deficiency was observed in only one of them, again showing no total correlation between the type of the mutation and secondary deficiencies of the studied proteins.

After the molecular classification of our patients, we decided to meticulously verify if any histopathological characteristic could be associated with this LGMD form. Histological findings showed typical dystrophic features in the majority of the patients, with the presence of moth-eaten and whorled fibers. Interestingly, we found a high frequency of patients with many fibers containing rimmed vacuoles, which were also visible using antibodies for sarcolemmal proteins. This alteration is not pathognomonic, because it can be observed in several other forms of MD, but its high frequency among our LGMD2I patients called our attention to the possible physiopathological mechanism of the disease. No correlation with the type of the mutation was observed, because patients presenting rimmed vacuoles were homozygous and heterozygous for different mutations, as well as carriers of the common mutation in the FKRP gene. No correlations were observed with secondary protein alterations as well, because immunofluorescence or Western blot analyses showed the same deficiencies of the 2-laminin associated to variation in the expression of the -DG and/or in calpain-3 amount in these patients. Additionally, rimmed vacuoles were observed in affected patients of different ages and stages of the disease, suggesting no direct correlation with the progression of the disease. We could therefore infer that the mechanism of muscle degeneration in LGMD2I could have started with a defective glycosylation of extracellular matrix proteins, followed by injury of the muscle, possibly involving necrosis of myofibers with loss of muscle internal architecture, in all stages of the disease.

In conclusion, the analysis of muscle proteins in patients with LGMD2I with different mutations in the FKRP gene suggests that there is no correlation between 2-laminin and -DG deficiencies in the muscle and the type of mutation in the FKRP gene. Secondary protein deficiencies thus are probably not the cause of the variability in the clinical course observed in LGMD2I patients.

	Acknowledgments

 
This work was supported by Fundação de Amparo a Pesquisa do Estado de São Paulo-Centro de Pesquisa, Inovação e Difusão (FAPESP-CEPID), Conselho Nacional de Desenvolvimento Científico e Tecnologico (CNPq), and Associação Brasileira de Distrofia Muscular (ABDIM).

The authors thank Dr. Rita Pavanello, Lucas S. Maia, Marta Canovas, Patrícia Kossugue, Telma Gouveia, Danielle Ayub, Poliana Martins, Paula Onofre, Dinorah Zilberztajn, Vanessa Lopes, and Viviane Muniz for scientific and technical help and the following researchers for kindly supplying us with antibodies: Dr. L.V.B. Anderson (in memoria), Dr. K.Campbell, Dr. J. Chamberlain, Dr. V. Nigro, Dr. G. Faulkner, Dr. E. Hoffmann, Dr. Nguyen Thi Man, Dr. G. Morris, and the Developmental Studies Hybridoma Bank, University of Iowa. We also thank the patients and their families.

	Footnotes

 
Received for publication April 30, 2008; accepted July 11, 2008

	Literature Cited

Top Summary Introduction Materials and Methods Results Discussion Literature Cited

 

Beedle AM, Nienaber PM, Campbell KP (2007) Fukutin-related protein associates with the sarcolemmal dystrophin-glycoprotein complex. J Biol Chem 282:16713–16717[Abstract/Free Full Text]

Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, Ponting CP, et al. (2001a) Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary 2-laminin deficiency and abnormal glycosylation of -dystroglycan. Am J Hum Genet 69:1198–1209[CrossRef][Medline]

Brockington M, Blake DJ, Torelli S, Brown CS, Muntoni F (2002) The gene for a novel glycosyltransferase is mutated in congenital muscular dystrophy MDC1C and limp girdle muscular dystrophy 2I. Neuromuscul Disord 12:233–234[CrossRef][Medline]

Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, Herrmann R, et al. (2001b) Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 10:2851–2859[Abstract/Free Full Text]

Brown SC, Torelli S, Brockington M, Yuva Y, Jimenez C, Feng L, Anderson L, et al. (2004) Abnormalities in -dystroglycan expression in MDC1 and LGMD2I muscular dystrophies. Am J Pathol 164:727–737[Abstract/Free Full Text]

Bushby KM (1995) Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord 5:71–74[CrossRef][Medline]

Bushby KM, Beckmann JS (2003) The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12–14, 2002. Neuromuscul Disord 13:80–90.[CrossRef][Medline]

Cohn RD (2005) Dystroglycan: important player in skeletal muscle and beyond. Neuromuscul Disord 15:207–217[CrossRef][Medline]

de Paula F, Vieira N, Starling A, Yamamoto LU, Lima B, Pavanello RC, Vainzof M, et al. (2003) Asymptomatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. Eur J Hum Genet 11:923–930[CrossRef][Medline]

Dubowitz V (1999) 68th ENMC international workshop (5th international workshop): on congenital muscular dystrophy, 9–11 April 1999, Naarden, The Netherlands. Neuromuscul Disord 9:446–454[CrossRef][Medline]

Ervasti JM, Campbell KP (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122:809–823[Abstract/Free Full Text]

Grewal KP, Hewitt JE (2003) Glycosylation defects: a new mechanism for muscular dystrophy? Hum Mol Genet 12:259–264[CrossRef]

Henry MD, Campbell KP (1999) Dystroglycan inside and out. Curr Opin Cell Biol 11:602–607[CrossRef][Medline]

Hewitt JE, Grewal PK (2003) Glycosylation defects in inherited muscle disease. Cell Mol Life Sci 60:251–258[CrossRef][Medline]

Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355:696–702[CrossRef][Medline]

MacLeod H, Pytel P, Wollmann R, Chelmicka-Schorr E, Silver K, Anderson RB, Waggoner D, et al. (2007) A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex. Neuromuscul Disord 17:285–289[CrossRef][Medline]

Martin PT (2003) Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. Glycobiology 13:55R–66R[Abstract/Free Full Text]

Matsumoto H, Hayashi YK, Kim DS, Ogawa M, Murakami T, Nogushi S, Nonaka I, et al. (2005) Congenital muscular dystrophy with glycosylation defects of -dystroglycan in Japan. Neuromuscul Disord 15:342–348[CrossRef][Medline]

Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, Herrrrmann R, Brown SC, et al. (2003) Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 53:537–542[CrossRef][Medline]

Mercuri E, Topaloglu H, Brockington M, Berardinelli A, Pichiecchio A, Santorelli F, Rutherford M, et al. (2006) Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol 673:251–257

Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, et al. (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418:417–422[CrossRef][Medline]

Poppe M, Cree L, Bourke J, Eagle M, Anderson LVB, Birchall D, Brockington M, et al. (2003) The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 60:1246–1251[Abstract/Free Full Text]

Quijano-Roy S, Carrera IM, Makri S, Mayer M, Maugenre S, Richard P, Berard C, et al. (2006) Brain MRI abnormalities in muscular dystrophy due to FKRP mutations. Brain Dev 28:232–242[CrossRef][Medline]

Schachter H, Vajsar J, Zhang W (2004) The role of defective glycosylation in congenital muscular dystrophy. Glycoconj J 20:291–300[CrossRef][Medline]

Sewry CA, Naom I, D'Alessandro M, Sorokin L, Bruno S, Wilson LA, Dubowitz V, et al. (1997) Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin 2 chain. Neuromuscul Disord 7:169–175[CrossRef][Medline]

Topaloglu H, Brockington M, Yuva Y, Talim B, Haliloglu G, Blake D, Torelli S, et al. (2003) FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 60:988–992[Abstract/Free Full Text]

Vainzof M, Passos-Bueno MR, Rapaport D, Pavanello RCM, Bulman DE, Zatz M (1992) Additional dystrophin fragment in Becker muscular dystrphy patients: correlation with the pattern of DNA deletions. Am J Med Genet 44:382–384[CrossRef][Medline]

Vainzof M, Passos-Bueno MR, Zatz M (2003) Immunological methods for the analysis of protein expression in neuromuscular diseases. Methods Mol Biol 217:355–378[Medline]

Vainzof M, Yamamoto LU, Gouveia TLF, Zatz M (2005) The contribution of protein analysis in the diagnosis of neuromuscular diseases. In Burgess VN, ed. Trends in Muscular Dystrophy Research. New York, Nova Biomedical Books, 245–262

Wicklund M, Hilton-Jones D (2003) The limb-girdle muscular dystrophies. Genetic and phenotypic definition of a disputed entity. Neurology 60:1230–1231[Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) All Versions of this Article: jhc.2008.951772v1 56/11/995    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yamamoto, L. U. Articles by Vainzof, M. Search for Related Content PubMed PubMed Citation Articles by Yamamoto, L. U. Articles by Vainzof, M. Social Bookmarking                         What's this?

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact